Combining Whole-Brain Radiotherapy with Gefitinib/Erlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis

doi:10.1155/2016/5807346

CORC > 兰州大学 > 兰州大学 > 第一临床医学院 > 期刊论文

	Combining Whole-Brain Radiotherapy with Gefitinib/Erlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis
	Zheng, MH; Sun, HT; Xu, JG; Yang, G; Huo, LM; Zhang, P; Tian, JH; Yang, KH; Yang, KH (reprint author), Lanzhou Univ, Evidence Based Med Ctr, Lanzhou 730000, Peoples R China.; Yang, KH (reprint author), Key Lab Evidence Based Med & Knowledge Translat G, Lanzhou 730000, Peoples R China.
刊名	BIOMED RESEARCH INTERNATIONAL
	2016
ISSN号	2314-6133
DOI	10.1155/2016/5807346
文献子类	Review
英文摘要	Background. To comprehensively assess the efficacy and safety of whole-brain radiotherapy (WBRT) combined with gefitinib/erlotinib for treatment of brain metastases (BM) from non-small-cell lung cancer (NSCLC). Methods. Databases including PubMed, EMBASE.com, Web of Science, and Cochrane Library were searched from inception to April 12, 2015. Studies on randomized controlled trials (RCTs) and case-control trials comparing WBRT combined with gefitinib/erlotinib versus WBRT alone for BM from NSCLC were included. Literature selection, data extraction, and quality assessment were performed independently by two trained reviewers. RevMan 5.3 software was used to analyze data. Results. A total of 7 trials involving 622 patients were included. Compared with WBRT alone or WBRT plus chemotherapy, WBRT plus gefitinib/erlotinib could significantly improve response rate (OR = 2.16, 95% CI: 1.35-3.47; P = 0.001), remission rate of central nervous system (OR = 6.06, 95% CI: 2.57-14.29; P < 0.0001), disease control rate (OR = 3.34, 95% CI: 1.84-6.07; P < 0.0001), overall survival (HR = 0.72, 95% CI: 0.58-0.89; P = 0.002), and 1-year survival rate (OR = 2.43, 95% CI: 1.51-3.91; P = 0.0002). In adverse events (III-IV), statistically significant differences were not found, except for rash (OR = 7.96, 95% CI: 2.02-31.34; P = 0.003) and myelosuppression (OR = 0.19, 95% CI: 0.07-0.51; P = 0.0010). Conclusions. WBRT plus gefitinib/ erlotinib was superior to WBRT alone and well tolerated in patients with BM from NSCLC.
学科主题	Biotechnology & Applied Microbiology ; Research & Experimental Medicine
出版地	NEW YORK
语种	英语
WOS记录号	WOS:000371582800001
内容类型	期刊论文
源URL	[http://ir.lzu.edu.cn/handle/262010/178540]
专题	第一临床医学院_期刊论文
通讯作者	Yang, KH (reprint author), Lanzhou Univ, Evidence Based Med Ctr, Lanzhou 730000, Peoples R China.; Yang, KH (reprint author), Key Lab Evidence Based Med & Knowledge Translat G, Lanzhou 730000, Peoples R China.
推荐引用方式 GB/T 7714	Zheng, MH,Sun, HT,Xu, JG,et al. Combining Whole-Brain Radiotherapy with Gefitinib/Erlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis[J]. BIOMED RESEARCH INTERNATIONAL,2016.
APA	Zheng, MH.,Sun, HT.,Xu, JG.,Yang, G.,Huo, LM.,...&Yang, KH .(2016).Combining Whole-Brain Radiotherapy with Gefitinib/Erlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis.BIOMED RESEARCH INTERNATIONAL.
MLA	Zheng, MH,et al."Combining Whole-Brain Radiotherapy with Gefitinib/Erlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis".BIOMED RESEARCH INTERNATIONAL (2016).